Trial Profile
Disposition of [¹⁴C]-LY3202626 Following Oral Administration in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2021
Price :
$35
*
At a glance
- Drugs LY 3202626 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 04 Jun 2020 Results published in the Drug Metabolism and Disposition
- 15 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 20 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.